Related Experiment Video
Updated: May 15, 2026

Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction
Published on: June 7, 2011
Matrix metalloproteinases: drug targets for myocardial infarction
Andriy Yabluchanskiy1, Yaojun Li, Robert J Chilton
1San Antonio Cardiovascular Proteomics Center, The University of Texas Health Science Center, San Antonio, TX 78245, USA.
Abstract:
Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Myocarditis III: Medical Management
Myocarditis I: Introduction
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

